NCT02974816CompletedNot Applicable
The Glooko Diabetes Mobile Monitoring and Management Advantage Study
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Glooko
- Enrollment
- 197
- Locations
- 8
- Primary Endpoint
- Change in HbA1c from baseline
Study Overview
Brief Summary
The purpose of this study is to compare HbA1c of insulin-treated subjects with type 2 diabetes managed via usual care alone and usual care augmented with remote monitoring using Glooko
Detailed Description
In this study, the investigator wants to evaluate if diabetes self-management supported by a mobile application, which captures a subject's blood glucose readings, lifestyle and medication information and shares it with the subject's certified diabetes educator (CDE) to enable remote monitoring, improves their glycemic control compared to standard of care.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act (HIPAA) or other privacy authorization prior to any participation in study.
- •Subject has self-reported type 2 diabetes.
- •Subject has HbA1c ≥ 7.5% and ≤ 12.5% measured within 30 days of screening visit.
- •Subject is on a stable diabetes therapeutic regimen of two or more diabetic medications (e.g., metformin plus one other antihyperglycemic agent) and/or insulin therapy for at least 2 months before screening visit. Dose changes or adjustments made within 2 months is acceptable as long as the patient has been on the medication regimen for 2 months or longer.
- •Subject is ≥ 18 and ≤ 75 years of age.
- •Subject is a male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. A urine pregnancy test is required for all female subjects unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
- •If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study):
- •Condoms, sponge, diaphragm, or intrauterine device;
- •Oral or parenteral contraceptives for 3 months prior to screening visit;
- •Vasectomized partner;
- •Total abstinence from sexual intercourse
- •Subject is able to speak, read and write in English
- •Subject has a Glooko compatible smartphone/device with an active data plan or access to Wi-Fi and downloaded at least one mobile application on their phone on their own.
- •Subject has performed self-monitoring of blood glucose at least five (5) times within two (2) weeks prior to screening visit.
Exclusion Criteria
- •Subject has type 1 diabetes.
- •Subject has advanced disease (physical or psychological) that would prevent them from being able to comply with study tasks and considered exclusionary by the study physicians.
- •Subject has been on medication or therapy within the last 2 months that severely affects blood glucose levels (e.g. corticosteroids).
- •Subject has visual impairment which severely limits his/her ability to see or use the mobile application.
- •Subject is a participant in another clinical study that has not been approved as a concomitant study by Glooko.
Outcomes
Primary Outcomes
Change in HbA1c from baseline
Time Frame: 24 weeks
Change in HbA1c from baseline
Secondary Outcomes
- Number of ER visits(Change from baseline)(12 and 24 weeks)
- Bolus insulin dose(Change from baseline)(12 and 24 weeks)
- Number of hospitalizations(Change from baseline)(12 and 24 weeks)
- Percentage of patients achieving </=7%(12 and 24 weeks)
- Weight(Change from baseline)(12 and 24 weeks)
- Mean blood glucose concentration(Change from baseline)(12 and 24 weeks)
- Basal insulin dose(Change from baseline)(12 and 24 weeks)
- Change in HbA1c from baseline(12 weeks)
- Problem Areas in Diabetes score(Change from baseline)(12 and 24 weeks)
- Change in Total insulin dose(Change from baseline)(12 and 24 weeks)
- Self-monitoring blood glucose frequency(12 and 24 weeks)
- Rate of hypoglycemic events (blood glucose level <70mg/dL)(12 and 24 weeks)
Investigators
Study Sites (8)
Loading locations...
Similar Trials
Completed
Phase 3
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)Diabetes Mellitus, Type 2NCT05823948Novo Nordisk A/S51
Completed
Not Applicable
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)Diabetes Mellitus, Type 2NCT03620357DexCom, Inc.72
Completed
Phase 3
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)Type 2 DiabetesNCT04605991Eli Lilly and Company187
Completed
Phase 4
Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of GlimepirideDiabetes MellitusNCT00633425Sanofi43
Active, not recruiting
Not Applicable
Assessment of blood glucose profile in type 2 diabetic patients after a one-week treatment with gliclazide 60 mg MR using both the glycaemic Holter method and multiple blood glucose samples.A double-blind, randomized, parallel group, placebo-controlled, exploratory study.Type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2008-002647-16-GBInstitut de Recherches Internationales Servier